CJC-1295 + Ipamorelin (5mg/5mg) · Research brief

CJC-1295 vs Ipamorelin vs MK-677: Effects Compared

Real Peptides Research TeamEditorial

Updated September 28, 20269 min read

42 WORDS

Short answer

Key takeaways

CJC-1295 is a GHRH receptor analog while ipamorelin and MK-677 both act at GHS-R1a, the ghrelin receptor, which is why the pairing of CJC-1295 with ipamorelin is treated as a two-receptor research combination rather than a duplicate stimulus.
The label CJC-1295 covers two distinct molecules: the DAC version with a multi-day duration, and modified GRF (1-29) which clears in minutes.
MK-677 has the deepest human evidence base of the three, including a two-year placebo-controlled trial published in the Annals of Internal Medicine in 2008 using 25 mg daily.
Ipamorelin's defining characteristic, established in Raun's 1998 European Journal of Endocrinology work, is growth hormone release without meaningful ACTH or cortisol stimulation.
Reduced insulin sensitivity, raised fasting glucose and lower-limb edema are the adverse signals most consistently reported for MK-677 in long-term human research.
None of the three compounds is an FDA-approved drug, and all are prohibited in sport under the WADA S2 growth hormone secretagogue category.

Most comparisons on this topic are quietly comparing the wrong molecule. The name CJC-1295 gets applied to two different compounds: the original long-acting analog carrying a Drug Affinity Complex (DAC), and the far shorter-acting modified GRF (1-29) sold as CJC-1295 no DAC. Any honest read on cjc-1295 vs ipamorelin vs mk-677 side effects and benefits has to separate those two first, because their pharmacokinetics differ by orders of magnitude.

We synthesise and characterise research-grade peptides in small batches for labs that run these comparisons for a living. The pattern in the questions we receive is consistent. People aren't confused about what growth hormone does. They're confused about which receptor each compound binds, and why that single fact reshapes the entire side-effect picture.

How do CJC-1295, ipamorelin and MK-677 compare on side effects and benefits?

CJC-1295 is a GHRH analog, ipamorelin is a selective ghrelin receptor agonist, and MK-677 (ibutamoren) is an orally active non-peptide agonist at that same ghrelin receptor. The injected peptides drive pulsatile growth hormone release. MK-677 sustains elevated IGF-1 around the clock, which is where its reported appetite, edema and insulin sensitivity signals originate.

The common oversimplification is treating this as three interchangeable options. It isn't. CJC-1295 and ipamorelin act on two separate receptors and are almost always studied as a pair for exactly that reason, while MK-677 duplicates the ipamorelin half of that pair in oral form with a much longer duration of action. What follows covers the receptor mechanisms, what published human research reports on the benefit side, and where the adverse-event profiles genuinely diverge.

Two receptors, one downstream signal

CJC-1295 and MK-677 don't compete for the same receptor, and that's the root of most confusion in this comparison. CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH), the hypothalamic peptide that binds the GHRH receptor on pituitary somatotrophs and raises cyclic AMP to trigger growth hormone release. Ipamorelin and MK-677 bind something else entirely: GHS-R1a, the growth hormone secretagogue receptor that ghrelin normally occupies.

Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) developed at Novo Nordisk and first described by Raun and colleagues in the European Journal of Endocrinology in 1998. MK-677, also called ibutamoren, isn't a peptide at all. It's an orally bioavailable small molecule that mimics ghrelin at the same receptor site.

Why does the two-receptor point matter? Ghrelin receptor agonists also blunt somatostatin, the physiological brake on growth hormone release. Pairing a GHRH analog with a ghrelin mimetic presses the accelerator while easing the brake, which is the entire reason the CJC-1295 + ipamorelin combination exists in research protocols rather than either compound alone.

And the DAC distinction is not academic. CJC-1295 with DAC binds serum albumin and persists for days. Modified GRF (1-29), the no-DAC version, clears in minutes. In our experience fielding supplier questions, the majority of people running a cjc 1295 vs mk 677 comparison are actually holding the no-DAC vial.

What the published literature reports on the benefit side

The evidence base behind these three compounds is wildly uneven, and MK-677 has the most human data of the three by a wide margin. Teichman and colleagues, reporting in the Journal of Clinical Endocrinology and Metabolism in 2006, found that single subcutaneous injections of CJC-1295 with DAC produced sustained elevations in growth hormone and IGF-1 in healthy adults, with IGF-1 remaining raised for days rather than hours.

Raun's 1998 work established ipamorelin's defining property: it released growth hormone comparably to GHRP-6 in animal models while, unlike GHRP-6 and GHRP-2, not meaningfully stimulating ACTH or cortisol at growth-hormone-releasing doses. That selectivity is the only reason ipamorelin is still a relevant research peptide almost three decades later.

MK-677 has the longest human exposure record. Nass and colleagues published a two-year, double-blind, placebo-controlled trial in the Annals of Internal Medicine in 2008 using 25 mg daily oral MK-677 in healthy older adults. Growth hormone and IGF-1 rose to levels typical of young adults, and fat-free mass increased by roughly a kilogram. Strength and function did not significantly improve.

Here's the point almost every mk 677 vs cjc 1295 ipamorelin discussion skips. Hepatic IGF-1 output tracks total integrated growth hormone exposure, but several growth-hormone-dependent effects in animal models track the pulse pattern itself, not the area under the curve. A flat 24-hour elevation and an episodic pulsatile stimulus are not the same signal even when IGF-1 readings look similar.

Where the reported side-effect profiles actually diverge

MK-677 carries the clearest documented adverse-event signal of the three, and it comes directly from its mechanism. The two-year trial reported increased appetite, transient lower-extremity edema, muscle pain, and a reduction in insulin sensitivity accompanied by increased fasting blood glucose. Appetite stimulation is not a side effect of MK-677 so much as an inevitable consequence of agonising the ghrelin receptor for 24 hours a day.

The injectable peptides report a different pattern. Published CJC-1295 work described injection-site reactions, transient flushing and headache. Ipamorelin's selectivity for growth hormone over prolactin and cortisol is its most cited advantage, though selectivity is not the same as an absence of risk, and long-term human data on ipamorelin simply does not exist.

One class-level caution applies to all three. Every growth hormone secretagogue works by raising IGF-1, and the growth hormone therapy literature has long documented fluid retention, arthralgia, carpal tunnel type symptoms and impaired glucose handling as IGF-1-linked effects. None of these compounds escapes that pathway.

Regulatory status is identical in one respect: none of the three is an FDA-approved drug. All are prohibited in sport under the World Anti-Doping Agency's S2 category, and the FDA has flagged several of these peptides as presenting significant safety concerns for use in compounding. Everything described here is laboratory research reporting, not medical or administration advice. These materials are supplied for research use only, not for human or veterinary administration, and anyone with a question about an animal's health should talk to their veterinarian rather than extrapolating from peptide literature.

CJC-1295 vs ipamorelin vs MK-677 side effects and benefits at a glance

This table separates the two CJC-1295 variants, which most comparisons collapse into one row. Reported effects are drawn from published research, not from outcome claims.

Compound	Receptor and route	Reported benefits in published research	Reported adverse signals	Bottom line for researchers
CJC-1295 with DAC	GHRH receptor, injected, albumin-bound multi-day duration	Sustained growth hormone and IGF-1 elevation from a single injection in healthy adults	Injection-site reactions, transient flushing and headache; tonic rather than pulsatile exposure	Longest-acting of the group, but its duration erodes the pulsatility that makes GHRH signalling physiologically distinct
CJC-1295 no DAC (modified GRF 1-29)	GHRH receptor, injected, clearance measured in minutes	Short, sharp growth hormone pulse that closely mimics endogenous GHRH signalling	Same local injection-site profile; effect window is brief	The version most commonly sold under the CJC-1295 label; verify which molecule the certificate of analysis describes
Ipamorelin	GHS-R1a ghrelin receptor, injected pentapeptide	Growth hormone release without meaningful ACTH or cortisol stimulation in the founding animal work	Limited published human safety data; appetite effects milder than other GHRPs but not absent	The selectivity benchmark of the GHRP class, and the standard research partner for a GHRH analog
MK-677 (ibutamoren)	GHS-R1a ghrelin receptor, orally active non-peptide	Two-year human trial showed restored growth hormone and IGF-1 levels plus roughly 1 kg fat-free mass gain	Increased appetite, lower-limb edema, muscle pain, reduced insulin sensitivity, raised fasting glucose	Most human data and the most convenient route, paired with the clearest metabolic cost of the three

What If: Common Research Sourcing Scenarios

What if my vial is labelled CJC-1295 but the certificate says modified GRF (1-29)?

Treat it as the no-DAC compound and adjust the study design accordingly. Modified GRF (1-29) and CJC-1295 with DAC share the same GHRH receptor target but have completely different exposure windows, so pooling results across the two produces noise, not data. The certificate of analysis is the authority here, not the product name on the label. Mass spectrometry identity confirmation on the batch document will show the actual molecular weight and settle the question in seconds.

What if a supplier can't produce a batch-specific certificate of analysis?

Don't use the material for anything you intend to publish or cite. A generic purity statement, or a certificate that isn't tied to a lot number, tells you nothing about the vial in front of you. Reputable suppliers publish HPLC purity and mass spectrometry identity per batch. A meaningful share of searches on this comparison include a competitor domain attached, which tells us researchers are comparing vendors at least as much as compounds. Documentation depth is the only comparison variable that actually matters at that stage.

What if the lyophilised powder looks different from the last batch?

Stop and check the certificate before reconstituting anything. Lyophilised peptide cake appearance varies legitimately with fill volume, freeze-drying cycle and excipient content, so a puck that looks flatter or more fragmented than last time isn't automatically a quality failure. What is a genuine problem: discolouration, visible moisture, or a vial that arrived with a broken cold chain. Peptide degradation from a temperature excursion produces no reliable visual signature, which is why storage logs beat visual inspection every time.

The unglamorous truth about this three-way comparison

Let's be direct about this: it isn't a fair fight, and treating it as one distorts the whole discussion. MK-677 has a two-year controlled human trial behind it and still didn't demonstrate improved strength or physical function despite normalising IGF-1. Ipamorelin and CJC-1295 have no comparable long-term human dataset at all, which means their apparently cleaner side-effect profile is partly a reflection of how little anyone has looked. Fewer reported adverse events is not the same finding as fewer adverse events. That distinction gets lost in every mk677 vs cjc 1295 ipamorelin thread online.

Researchers comparing these compounds directly can review the batch documentation for CJC-1295 no DAC, ipamorelin, the pre-paired CJC-1295 and ipamorelin blend and MK-677, along with our full certificate of analysis library and the wider research catalog.

Anyone weighing cjc-1295 vs ipamorelin vs mk-677 side effects and benefits eventually arrives at the same uncomfortable realisation: the compound you choose matters less than whether you can prove what's in the vial. Two research groups running identical protocols with identically labelled material can produce opposite results purely because one batch was 98% pure and the other was 82% with an unidentified related substance. Receptor pharmacology is the interesting part of this comparison. Analytical documentation is the part that decides whether the data means anything.

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

CJC-1295 acts at the GHRH receptor, while ipamorelin and MK-677 both act at GHS-R1a, the ghrelin receptor. The two peptides are injected and produce pulsatile growth hormone release; MK-677 is taken orally and sustains IGF-1 elevation across 24 hours. That sustained exposure is why MK-677's published research reports appetite increase, lower-limb edema and reduced insulin sensitivity, signals that are less prominent in the injected peptide literature.

Neither is objectively better; they answer different research questions. The CJC-1295 and ipamorelin pairing stimulates two separate receptors simultaneously, producing a pulsatile release pattern closer to endogenous physiology. MK-677 delivers a flatter, continuous elevation with far more long-term human data behind it, including a two-year placebo-controlled trial. If pulse pattern is the variable under study, the peptide pair is the appropriate model.

The Drug Affinity Complex allows the molecule to bind serum albumin, extending its duration to days rather than minutes. CJC-1295 no DAC is chemically modified GRF (1-29) and clears rapidly, producing a short growth hormone pulse. Most material sold online under the CJC-1295 name is the no-DAC version, so the certificate of analysis and its mass spectrometry identity data are the only reliable way to confirm which molecule you have.

Raun and colleagues, publishing in the European Journal of Endocrinology in 1998, found that ipamorelin released growth hormone comparably to GHRP-6 in animal models but did not meaningfully stimulate ACTH or cortisol at those same doses. Earlier growth hormone releasing peptides such as GHRP-2 and GHRP-6 raised cortisol and prolactin alongside growth hormone. That selectivity is ipamorelin's defining property and the reason it remains a reference compound in secretagogue research.

The two-year trial published in the Annals of Internal Medicine in 2008 reported increased appetite, transient edema of the lower extremities, muscle pain, decreased insulin sensitivity and increased fasting blood glucose. Appetite stimulation is mechanistically unavoidable, since MK-677 agonises the same receptor ghrelin uses to signal hunger. The glucose and insulin findings are the most clinically meaningful signal in that dataset.

They can be purchased in most jurisdictions as research chemicals for laboratory use, but none is an FDA-approved drug and none may be sold or marketed for human or veterinary consumption. All three fall under the World Anti-Doping Agency's S2 prohibited category as growth hormone secretagogues. Suppliers selling them legitimately do so on a research-use-only basis with batch documentation.

Pricing varies widely by vial size, purity specification and supplier, and cost per milligram tends to fall as vial size increases. What changes cost more than anything is documentation depth: suppliers that run per-batch HPLC purity and mass spectrometry identity testing and publish those certificates carry higher overheads than those selling undocumented material. Comparing price without comparing certificates is not a real comparison.

Prioritise primary literature indexed on PubMed over forum summaries and vendor blog content. The core papers are Raun's 1998 ipamorelin characterisation in the European Journal of Endocrinology, Teichman's 2006 CJC-1295 pharmacokinetic work in the Journal of Clinical Endocrinology and Metabolism, and Nass's 2008 two-year MK-677 trial in the Annals of Internal Medicine. Anything presented without a traceable citation should be treated as commentary, not evidence.

Lyophilised peptide should be kept frozen and protected from light and moisture before reconstitution, with reconstituted solutions refrigerated and used within a limited window. Repeated freeze-thaw cycles and humidity exposure are the two most common causes of degradation. Critically, peptide degradation from a temperature excursion leaves no reliable visual signature, so shipping records and storage logs are more informative than inspecting the vial.

Published data does not allow a clean head-to-head answer, because no controlled trial has compared them directly under the same conditions. What research does show is that MK-677 sustains IGF-1 elevation continuously across 24 hours with once-daily oral administration, while a GHRH analog paired with a GHRP produces episodic pulses. Similar IGF-1 readings from these two stimulus patterns are not biologically equivalent.

Yes, and combining them is the standard design in secretagogue research precisely because they target different receptors. CJC-1295 activates the GHRH receptor while ipamorelin agonises GHS-R1a and reduces somatostatin inhibition, producing a greater growth hormone response than either compound generates alone. Pre-blended research vials exist for this reason, though single-compound vials give a study more control over the ratio.

A useful certificate is batch-specific and tied to the lot number on the vial. It should include HPLC purity as a percentage, mass spectrometry confirming the molecular weight matches the stated sequence, and the test date. Generic certificates with no lot reference, or purity claims with no accompanying chromatogram, tell you nothing verifiable about the material you received.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA